Company profile
Enodia Therapeutics
Targeting protein degradation at the point of synthesis
- Industry
- Biotechnology Research
- Employees
- 13
- Headquarters
- Paris
- Founded
- 2025
- Office locations
- 1
Enodia Therapeutics company summary
Enodia Therapeutics is a company in the Biotechnology Research industry, headquartered in Paris, founded in 2025. On LinkedIn the company has around 13 employees.
What technology does Enodia Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Enodia Therapeutics
Enodia Therapeutics is a French biotech company building a proprietary small-molecule platform that selectively modulates the SEC61 translocon, a central control point of the protein secretion pathway. By intervening at the point of synthesis, Enodia redirects disease-driving secreted and transmembrane proteins toward early degradation, before they mature or exert pathological effects, while preserving normal cellular function. Leveraging a deep, well-characterized chemical space of SEC61 inhibitors, together with proteomics and machine-learning–guided drug design, Enodia enables highly selective, upstream intervention across multiple indications, starting with inflammatory and autoimmune diseases.
Where is Enodia Therapeutics located?
Enodia Therapeutics lists 1 location.
Compare companies similar to Enodia Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Enodia Therapeutics enodiatx.com | Biotechnology Research | 13 | 2025 | Paris |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Enodia Therapeutics
What does Enodia Therapeutics do?
Enodia Therapeutics is a French biotech company building a proprietary small-molecule platform that selectively modulates the SEC61 translocon, a central control point of the protein secretion pathway. By intervening at the point of synthesis, Enodia redirects disease-driving secreted and transmembrane proteins toward early degradation, before they mature or exert pathological effects, while preserving normal cellular function. Leveraging a deep, well-characterized chemical space of SEC61 inhibitors, together with proteomics and machine-learning–guided drug design, Enodia enables highly selective, upstream intervention across multiple indications, starting with inflammatory and autoimmune diseases.
How many employees does Enodia Therapeutics have?
Enodia Therapeutics has around 13 employees on LinkedIn.
Where is Enodia Therapeutics headquartered?
Enodia Therapeutics is headquartered in Paris.
When was Enodia Therapeutics founded?
Enodia Therapeutics was founded in 2025.
Build a lead list from companies like Enodia Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.